Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Sponsor: Bausch & Lomb Incorporated
Listed as NCT04139798, this PHASE3 trial focuses on Dry Eye Disease (DED) and remains completed. Sponsored by Bausch & Lomb Incorporated, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Apr 2021 — Apr 2022 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch & Lomb Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United States , Cranberry Township, United States , Danbury, United States , Edgewood, United States , El Paso, United States , Fort Myers, United States , Glendale, United States , Indianapolis, United States , Jacksonville, United States , Kansas City, United States and 18 more locations